← Leaderboards
Michael L. Terrin
Clinical Trials And Surveys Corporation
$42,991,557
Attributed
$59,951,629
Total exposure
10
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $9.9M · FY2005–24$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$59,951,629 · 10
By mechanism
U01$32,779,596 · 2
R01$16,883,475 · 2
U24$7,894,188 · 1
U19$997,942 · 1
UG3$657,935 · 1
N01$637,539 · 2
Top collaborators
- Rose Marie Viscardi13 shared
- Namasivayam Ambalavanan6 shared
- Bernard Timothy Baxter6 shared
- John A Curci6 shared
- Pamela Donohue6 shared
- David A Kaufman6 shared
- Jon Steven Matsumura6 shared
- Ken B Waites6 shared
Others in their field
Top investigators on “Research Personnel”
- David Heimbrook · Leidos Biomedical Research, Inc.$701,463,488
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Leonard Freedman · Leidos Biomedical Research, Inc.$557,978,666
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David R. Weir · University Of Michigan At Ann Arbor$364,053,504
- Judith S. Currier · University Of California Los Angeles$284,675,012
Research focus
Research PersonnelSymposiumMonitorMeetingsReagentCommunicationNational Heart, Lung, And Blood InstituteWeb SiteFundingTranslatingLung DiseasesProgramsStem CellsRandomizedCellular BiologyBasic SciencePilot ProjectsClinical TrialsData ManagementReportingProtocols DocumentationAwardLeadHematological Disease
Grant awards (49)
Consortium-Wide Coordinating Core$181,570
U19 · FY2024 · AI · contact PI
Consortium-Wide Coordinating Core$220,546
U19 · FY2023 · AI · contact PI
PCTC Administrative Coordinating Center$1,111,647
U24 · FY2022 · HL · contact PI
Consortium-Wide Coordinating Core$187,987
U19 · FY2022 · AI · contact PI
PCTC Administrative Coordinating Center$1,121,637
U24 · FY2021 · HL · contact PI
Consortium-Wide Coordinating Core$203,975
U19 · FY2021 · AI · contact PI
PCTC Administrative Coordinating Center$1,131,510
U24 · FY2020 · HL · contact PI
1/2 Allogeneic Human Mesenchymal Stem Cell (MSC) Injection in Patients with Hypoplastic Left Heart Syndrome: A Phase IIb Clinical Trial$657,935
UG3 · FY2020 · HL
Consortium-Wide Coordinating Core$203,864
U19 · FY2020 · AI · contact PI
PCTC Administrative Coordinating Center$1,184,212
U24 · FY2019 · HL · contact PI
PCTC Administrative Coordinating Center$1,135,110
U24 · FY2019 · HL · contact PI
Azithromycin To Prevent BPD In Ureaplasma-Infected Preterms$464,577
R01 · FY2019 · HD · contact PI
PCTC Administrative Coordinating Center$1,145,433
U24 · FY2018 · HL · contact PI
Azithromycin To Prevent BPD In Ureaplasma-Infected Preterms$519,779
R01 · FY2018 · HD
Non-Invasive Treatment of Abdominal Aortic Aneurysm Clinical Trial (N-TA^3CT )$1,388,548
R01 · FY2017 · AG · contact PI
Azithromycin To Prevent BPD In Ureaplasma-Infected Preterms$679,004
R01 · FY2017 · HD
PCTC Administrative Coordinating Center$526,791
U24 · FY2017 · HL · contact PI
Non-Invasive Treatment of Abdominal Aortic Aneurysm Clinical Trial (N-TA^3CT )$2,591,041
R01 · FY2016 · AG · contact PI
PCTC Administrative Coordinating Center$537,848
U24 · FY2016 · HL · contact PI
Progenitor Cell Biology Consortium Administrative Coordinating Center$3,517,404
U01 · FY2015 · HL · contact PI
Azithromycin to prevent BPD in ureaplasma-infected preterms.$567,292
R01 · FY2015 · HD
Azithromycin to prevent BPD in ureaplasma-infected preterms.$127,500
R01 · FY2015 · HD
Progenitor Cell Biology Consortium Administrative Coordinating Center$5,202,276
U01 · FY2014 · HL · contact PI
Azithromycin to prevent BPD in ureaplasma-infected preterms.$571,913
R01 · FY2014 · HD
Progenitor Cell Biology Consortium Administrative Coordinating Center$6,689,551
U01 · FY2013 · HL · contact PI
Non-Invasive Treatment of Abdominal Aortic Aneurysm Clinical Trial (N-TA^3CT )$2,510,320
R01 · FY2013 · AG · contact PI
Azithromycin to prevent BPD in ureaplasma-infected preterms.$570,381
R01 · FY2013 · HD
Non-Invasive Treatment of Abdominal Aortic Aneurysm Clinical Trial (N-TA^3CT )$99,602
R01 · FY2013 · AG · contact PI
Progenitor Cell Biology Consortium Administrative Coordinating Center$5,835,427
U01 · FY2012 · HL · contact PI
Non-Invasive Treatment of Abdominal Aortic Aneurysm Clinical Trial (N-TA^3CT )$2,658,963
R01 · FY2012 · AG · contact PI
Azithromycin to prevent BPD in ureaplasma-infected preterms.$597,460
R01 · FY2012 · HD
Non-Invasive Treatment of Abdominal Aortic Aneurysm Clinical Trial (N-TA^3CT )$2,914,152
R01 · FY2011 · AG · contact PI
Progenitor Cell Biology Consortium Administrative Coordinating Center$2,228,983
U01 · FY2011 · HL · contact PI
Azithromycin to prevent BPD in ureaplasma-infected preterms.$622,943
R01 · FY2011 · HD
Progenitor Cell Biology Consortium Administrative Coordinating Center$4,062,690
U01 · FY2010 · HL · contact PI
FOCUS Data Coordinating Center$123,936
U01 · FY2010 · HL · contact PI
Progenitor Cell Biology Consortium Administrative Coordinating Center$2,370,748
U01 · FY2009 · HL · contact PI
FOCUS Data Coordinating Center$63,000
U01 · FY2008 · HL · contact PI
FOCUS Data Coordinating Center$928,989
U01 · FY2007 · HL · contact PI
Doxycycline Treatment of Abdominal Aortic Aneurysm: Planning$100,954
R34 · FY2007 · AG · contact PI
FOCUS Data Coordinating Center$63,000
U01 · FY2007 · HL · contact PI
FOCUS Data Coordinating Center$443,837
U01 · FY2006 · HL · contact PI
FOCUS Data Coordinating Center$441,748
U01 · FY2005 · HL
FOCUS Data Coordinating Center$411,208
U01 · FY2004 · HL
FOCUS Data Coordinating Center$396,799
U01 · FY2003 · HL
PEDIATRIC HYDROXYUREA PHASE III CLINICAL TRIAL - MCC$637,539
N01 · FY2000 · HB
MSH PATIENTS FOLLOW-UP$0
N01 · FY2000 · HB
MSH PATIENTS FOLLOW-UP$0
N01 · FY2000 · HB
PEDIATRIC HYDROXYUREA PHASE III CLINICAL TRIAL - MCC$0
N01 · FY2000 · HB